Cenerimod, a selective S1P₁ receptor modulator, improves organ-specific disease outcomes in animal models of Sjogren's syndrome.

ABSTRACT:

Background

Sjögren's syndrome is a systemic autoimmune disease characterized by immune cells predominantly infiltrating the exocrine glands and frequently forming ectopic lymphoid structures. These structures drive a local functional immune response culminating in autoantibody production and tissue damage, associated with severe dryness of mucosal surfaces and salivary gland hypofunction. Cenerimod, a potent, selective and orally active sphingosine-1-phosphate receptor 1 modulator, inhibits the egress of lymphocytes into the circulation. Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjögren's syndrome.

Methods

Cenerimod was administered in two established models of Sjögren's syndrome; firstly, in an inducible acute viral sia

SUBMITTER: Gerossier E 

PROVIDER: S-EPMC8628476 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature